Optimization of the choice of neuroprotective therapy regimens in patients with cerebrovascular diseases (CVD), taking into account the synergism of drug interactions, is a basic approach in clinical practice. Unfortunately, modern pharmacology has no unified way of establishing synergistic spectra of drug actions, which would allow systematic investigation of the effects of combinations of drugs. An approach based on studying detailed mechanisms of action suggested combinations of drugs with the greatest possible synergism (by summation and potentiation of effects) for various directions in the treatment of neurological diseases. Examples of rational neuroprotection are considered, using Cortexin, citicoline, and antioxidants.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
A. Nalbandian, K. Sehgal, A. Gupta, et al., “Post-acute COVID-19 syndrome,” Nat. Med., 27, No. 4, 601–615 (2021), https://doi.org/10.1038/s41591-021-01283-z.
“Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019,” Lancet, 20, 795–820 (2021), https://doi.org/10.1016/S1474-4422(21)00252-0.
X. Tong, Q. Yang, M. D. Ritchey, et al., “The burden of cerebrovascular disease in the United States,” Prev. Chronic Dis., 16, 180411 (2019), https://doi.org/10.5888/pcd16.180411.
Federal State Statistics Service, https://rosstat.gov.ru.
World Population Prospects: Revised Edition of 2021 (report), World Population Prospects (2021), https://www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/undesa_pd_2021_egm_wpp2022_session.
R. G. Oganov, V. I. Simanenkov, I. G. Bakulin, et al., “Comorbid pathologies in clinical practice. Algorithms for diagnosis and treatment,” Kardiovask. Ter. Profilakt. 18, No. 1, 5–66 (2019), https://doi.org/10.15829/1728-8800-2019-1-5-66.
M. Melissa, D. Favreault, and W. Richard, The Risk and Costs of Severe Cognitive Impairment at Older Ages: Literature Review and Projection Analyses, Urban Institute (2021), https://aspe.hhs.gov/reports/risk-costs-severe-cognitive-impairment-older-ages-literature-review-projection-analyses-0.
R. C. C. Chang and Y. S. Ho, “Introductory chapter: concept of neuroprotection – a new perspective, neuroprotection,” Intech Open, 23, No. 5, 274636 (2019), https://doi.org/10.5772/intechopen.85631.
R. Crupi, D. Impellizzeri, and S. Cuzzocrea, “Role of metabotropic glutamate receptors in neurological disorders,” Front. Mol. Neurosci., 12, 20–28 (2019), https://doi.org/10.3389/fnmol.2019.00020.
M. V. Putilina, “Combined use of neuroprotectors in the treatment of cerebrovascular diseases,” Zh. Nevrol. Psikhiatr., 116, No. 11, 58–63 (2016), https://doi.org/10.17116/jnevro201611611158-63.
C. Rodriguez, J. Agulla, and M. Delgado-Esteban, “Refocusing the brain: New approaches in neuroprotection against ischemic injury,” Neurochem. Res., 46, 51–63 (2021), https://doi.org/10.1007/s11064-020-03016-z.
G. Satyanarayana, D. Chakradhar, and S. Melvin, “Neuroprotective agents in acute ischemic stroke – A reality check,” Biomed. Pharmacother., 109, 2539–2547 (2019), https://doi.org/10.1016/j.biopha.2018.11.041.
M. V.Putilina, and N. V. Teplova, Rational Pharmacotherapy of Chronic Cerebral Ischemia. Clinical Guidelines, MEDpress-Inform, Moscow (2019).
E. F. Barinov, E. A. Statinova, V. S. Sokhina, and T. I. Faber, “Risks of progression of cerebrovascular pathology associated with the activity of the purinergic system of the brain,” Zh. Nevrol. Psikhiatr., 120, No. 10, 118–124 (2020), https://doi.org/10.17116/jnevro2020120101118.
H. Sharma, and A. Sharma, “Neuromodulation as a basic platform for neuroprotection and repair after spinal cord injury,” Prog. Brain Res., 266, 269–300 (2021), https://doi.org/10.1016/bs.pbr.2021.06.012.
R. Faria, “Receptors P1 and P2 as targets for drug therapy in humans,” Intech Open, 020.https://doi.org/10.5772/intechOpen, https://doi.org/10.5772/intechopen.78115.
O. A. Gromova, I. Yu. Torshin, M. V. Putilina, et al., “Selection of neuroprotective therapy regimens in patients with chronic cerebral ischemia, taking account of the synergy of drug interactions,” Zh. Nevrol. Psikhiatr., 120, No. 8, 42–50 (2020), https://doi.org/10.17116/jnevro202012008142.
I. Y.Torshin and K. V. Rudakov, “Combinatorial analysis of the solvability properties of the problems of recognition and completeness of algorithmic models. part 1: factorization approach,” Pattern Recognition and Image Analysis (Advances in Mathematical Theory and Applications), 27, No. 1, 16–28 (2017).
M. Wambaugh, S. Denham, M. Ayala, et al., “Synergistic and antagonistic drug interactions in the treatment of systemic fungal infections,” Elife, 9, 23–29 (2020), https://doi.org/10.7554/eLife.54160.
M. V. Putilina, “Complex neuroprotective therapy of the sequelae of chronic brain ischemia,” Meditsinsk. Sov., 9–10, 92–97 (2010).
A. I. Chernykh, Yu. K. Komleva, Ya. V. Gorina, et al., “Pro-inflammatory phenotype of perivascular astroglia and CD133+ endotheliocyte progenitor cells in a murine model of Alzheimer’s disease,” Fundament. Klin. Med., 3, No. 1, 6–15 (2018), https://doi.org/10.23946/2500-0764-2018-3-1-6-15.
G. Lima, J. Doorduin, and H. C. Klein, “Brain-derived neurotrophic factor in brain disorders: Focus on neuroinflammation,” Mol. Neurobiol., 56, 3295–3312 (2019), https://doi.org/10.1007/s12035-018-1283-6.
M. A. Hannan, R. Dash, A. A. M. Sohag, et al., “Neuroprotection against oxidative stress: phytochemicals targeting TrkB signaling and the Nrf2-ARE antioxidant system,” Front. Mol. Neurosci., 13, 116 (2020), https://www.frontiersin.org/articles//full. https://doi.org/10.3389/fnmol.2020.00116.
X. Zhou, Q. R. Smith, and X. Liu, “Brain-penetrating peptides and peptide-drug conjugates for overcoming the blood–brain barrier and combating diseases of the central nervous system.” WIRES Nanomed. Nanobiotechnol., e1695 (2021), https://doi.org/10.1002/wnan.1695.
R. Soudy, R. Kimura, and A. Patel, “Short amylin receptor antagonist peptides improve memory deficits in Alzheimer’s disease mouse model,” Sci. Rep., 9, 10942 (2019), https://doi.org/10.1038/s41598-019-47255-9.
J. Lee and C. Kim, “peptide materials for smart therapeutic applications,” Macromol. Res., 29, 2–14 (2021), https://doi.org/10.1007/s13233-021-9011-x.
N. Shang, C. Meram, N. Bandara, and J. Wu, “Protein and peptides for elderly health,” Adv. Protein Chem. Struct. Biol., 112, 265–308 (2018), https://doi.org/10.1016/bs.apcsb.2018.03.003.
I. N. Tyurenkov, D. V. Kurkin, A. V. Kalatanova, et al., “Comparative study of the effects of Cortexin, Cerebrolysin and Actovegin on memory, cerebral circulation, and hippocampal structure in rats with chronic cerebral ischemia,” Zh. Nevrol. Psikhiatr., 120, No. 8, 83–89 (2020), https://doi.org/10.17116/jnevro202012008183.
M. V. Putilina, Z. Yu. Mutovina, O. V. Kurushina, et al., “Determination of the prevalence of postcovid syndrome and assessment of the efficacy of the drug Cortexin in the treatment of neurological disorders in patients with postcovid syndrome,” Zh. Nevrol. Psikhiatr., 122, No. 1, 84–90 (2022), https://doi.org/10.17116/jnevro202212201184.
A. I. Fedin, G. N. Bel’skaya, O. V. Kurushina, et al., “Dose-dependent effects of Cortexin in chronic cerebral ischemia (results of a multicenter randomized controlled study).,” Zh. Nevrol. Psikhiatr., 118, No. 9, 35–42 (2018), https://doi.org/10.17116/jnevro201811809135.
A. A. Yakovlev and N. V. Gulyaeva, “Molecular partners of Cortexin in the brain,” Neirokhimiya,. 33, 91–96 (2017), https://doi.org/10.1134/S1819712416040164.
D. Kurkin, D. Bakulin, E. Morkovin, et al., “Neuroprotective action of Cortexin, Cerebrolysin and Actovegin in acute or chronic brain ischemia in rats,” PLoS One, 16, No. 7, E0254493 (2021), https://doi.org/10.1371/journal.pone.0254493.
M. V. Putilina, “Personalized selection of choline precursors in evidence-based medicine,” Zh. Nevrol. Psikhiatr., 120, No. 6, 144–151 (2020), https://doi.org/10.17116/jnevro2020120061144.
A. Martí-Carvajal, C. Valli, I. Solà, et al., “Citicoline for treating people with acute ischemic stroke. Cochrane Systematic Review,” Cochrane Database Syst. Rev., 8, No. 8, CD013066 (2020), https://doi.org/10.1002/14651858.CD013066.pub2.
V. V. Mashin, L. A. Belova, I. R. Bakhtogarimov, et al., “Multicenter observational program for evaluating the efficacy of the drug Recognan (citicoline) in correcting cognitive impairments in patients with chronic cerebrovascular pathology,” Zh. Nevrol. Psikhiatr., 117, No. 8, 39–43 (2017).
D. Petrova, D. Maslarov, I. Angelov, and D. Zekin, “Analysis of therapeutic efficacy of citicoline in patients with vertigo of central origin and vascular aetiology,” Am. J. Neuroprotec. Neuroregen., 4, No. 1, 1–8 (2012), https://doi.org/10.1166/ajnn.2012.1043.
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 122, No. 5, Iss. 1, pp. 17–22, May, 2022.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Putilina, M.V., Teplova, N.V. Drug Synergism as the Basis of Rational Neuroprotection. Neurosci Behav Physi 52, 1207–1211 (2022). https://doi.org/10.1007/s11055-023-01349-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11055-023-01349-0